Free Trial

Teacher Retirement System of Texas Has $22.02 Million Stake in Cencora, Inc. $COR

Cencora logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Teacher Retirement System of Texas cut its Cencora stake by 30.8% in Q4, selling 29,049 shares and retaining 65,198 shares valued at about $22.02 million.
  • Institutional investors own 97.52% of Cencora, with large funds such as Marshall Wace (+518.9%), UBS (+528.9%) and Vanguard (+4.1%) substantially increasing positions while some others trimmed theirs.
  • Cencora reported Q4 EPS $4.08 (a beat) and revenue up 5.5% YoY, has a market cap of about $59.8B, pays a quarterly dividend of $0.60 (0.8% yield), and carries a MarketBeat consensus of Moderate Buy with a $398.17 target.
  • Five stocks to consider instead of Cencora.

Teacher Retirement System of Texas decreased its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 30.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 65,198 shares of the company's stock after selling 29,049 shares during the period. Teacher Retirement System of Texas' holdings in Cencora were worth $22,021,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of COR. Marshall Wace LLP increased its holdings in shares of Cencora by 518.9% during the third quarter. Marshall Wace LLP now owns 1,995,118 shares of the company's stock worth $623,534,000 after buying an additional 1,672,762 shares in the last quarter. Mizuho Markets Americas LLC increased its holdings in shares of Cencora by 116.4% during the third quarter. Mizuho Markets Americas LLC now owns 212,800 shares of the company's stock worth $66,506,000 after buying an additional 1,511,906 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Cencora by 528.9% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company's stock worth $461,250,000 after buying an additional 1,241,186 shares in the last quarter. Viking Global Investors LP increased its holdings in shares of Cencora by 95.0% during the second quarter. Viking Global Investors LP now owns 2,081,732 shares of the company's stock worth $624,207,000 after buying an additional 1,013,913 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Cencora by 4.1% during the third quarter. Vanguard Group Inc. now owns 23,395,547 shares of the company's stock worth $7,311,810,000 after buying an additional 916,506 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.

Cencora Stock Performance

Shares of Cencora stock opened at $307.60 on Friday. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51. The firm has a market cap of $59.84 billion, a P/E ratio of 36.97, a P/E/G ratio of 1.45 and a beta of 0.72. The firm has a 50 day simple moving average of $337.33 and a 200 day simple moving average of $343.02. Cencora, Inc. has a fifty-two week low of $271.00 and a fifty-two week high of $377.54.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, beating analysts' consensus estimates of $4.04 by $0.04. The business had revenue of $85.93 billion during the quarter, compared to analyst estimates of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. Cencora's revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter last year, the business posted $3.73 earnings per share. Sell-side analysts predict that Cencora, Inc. will post 17.57 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, March 2nd. Investors of record on Friday, February 13th were issued a $0.60 dividend. The ex-dividend date of this dividend was Friday, February 13th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.8%. Cencora's dividend payout ratio (DPR) is currently 28.85%.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on COR shares. Wells Fargo & Company raised their price objective on shares of Cencora from $405.00 to $429.00 and gave the stock an "overweight" rating in a report on Tuesday, February 10th. Robert W. Baird set a $415.00 price objective on shares of Cencora in a report on Tuesday, January 13th. Barclays raised their price objective on shares of Cencora from $400.00 to $425.00 and gave the stock an "overweight" rating in a report on Friday, February 13th. JPMorgan Chase & Co. raised their price target on shares of Cencora from $417.00 to $419.00 and gave the company an "overweight" rating in a report on Tuesday, February 10th. Finally, Bank of America lowered their price target on shares of Cencora from $380.00 to $360.00 and set a "neutral" rating for the company in a report on Monday, January 5th. Twelve equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $398.17.

Read Our Latest Research Report on COR

Cencora Profile

(Free Report)

Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

See Also

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR - Free Report).

Institutional Ownership by Quarter for Cencora (NYSE:COR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cencora Right Now?

Before you consider Cencora, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.

While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines